Kali-Extracts Confirms $20 Million Mobile Cannabis Extraction Capacity Presentation Scheduled Tomorrow
June 10 2019 - 9:43AM
InvestorsHub NewsWire
Kali-Extracts Confirms $20 Million
Mobile Cannabis Extraction Capacity Presentation Scheduled
Tomorrow
Dallas, TX -- June 10, 2019 --
InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today confirmed a presentation scheduled for
tomorrow on Tuesday, June 11th were management will
present KALY’s mobile cannabis extraction capacity to be utilized
in its recently announced contract with a New York State Licensed
Hemp Cultivation Operation anticipated to generate an estimated $5
million in revenue for KALY. The presentation will include
details on how the mobile cannabis extraction capacity will be
utilized to potentially expand the $5 million contract into
potentially more than $20 million in similar
contracts.
KALY owns and operates a U.S.
Patented Cannabis Extraction Process. In addition to its
direct cannabis extraction business, the company is advancing
biotechnology research for the future production of cannabis
extract centric pharmaceuticals and at the same time, the company
is currently generating revenue from the sale of CBD infused
consumer products.
KALY is
primarily a biopharmaceutical company focused on discovering,
developing and commercializing novel therapeutics from a
proprietary cannabinoid product platform in a broad range of
disease areas. In the fourth quarter of last year, 2018, KALY
acquired NCM Biotech (NCMB). In NCMB’s four years of
operations, the company has established a leading position in the
development of plant-derived cannabinoid therapeutics through a
proven drug discovery and patented development process. The
resulting intellectual property portfolio and the established
regulatory and manufacturing expertise have created a significant
opportunity. KALY has a deep pipeline of cannabinoid product
candidates including four distinct compounds. KALY has
completed the first stage of clinical development and testing for a
Chronic Obstructive Pulmonary Disease (COPD) therapy and is
currently conducting phase one development and trials for compounds
targeting Cancer Pain Management, Type 2 Diabetes and
Epilepsy.
KALY is
not relying on its biopharmaceutical development strategy alone to
insure the company’s long-term success. With the popularity
of cannabis extracts for infusion into various consumer products,
KALY’s patented extraction process offers arguably the highest
quality extract to the infusion market. Drawing on KALY’s
patented cannabis extraction expertise, in addition to winning the
$5 million extraction contract mentioned above, KALY has partnered
with Puration (USOTC:
PURA) to lend its extraction expertise in the production of
EVERx CBD Sports Water, the leading CBD infused beverage for the
sports nutrition market. KALY has also introduced its own CBD
confections line, Hemp4mula with CBD infused gum already on the
market and gummies on the way. Hemp4mula is available on the
Ecommerce site USMJ.com hosted by North American Cannabis Holdings,
Inc. (USOTC:
USMJ) (aka USMJ). KALY’s non-pharmaceutical extraction
revenue strategy offers a business line that can stand alone, and
at the same time provide KALY with the long-term staying power to
bring its cannabis extract biopharmaceutical products to
market.
To learn more about the company
visit https://www.kali-extracts.com/
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
North American Cannabis (CE) (USOTC:USMJ)
Historical Stock Chart
From Aug 2024 to Sep 2024
North American Cannabis (CE) (USOTC:USMJ)
Historical Stock Chart
From Sep 2023 to Sep 2024